EMA Application withdrawn: Nidlegy (bifikafusp alfa;onfekafusp alfa) — Philogen S.p.A.

View source ↗

Summary

The European Medicines Agency has withdrawn the application for Nidlegy (bifikafusp alfa; onfekafusp alfa) indicated for melanoma, submitted by Philogen S.p.A.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• bifikafusp alfa (bifikafusp alfa)
• onfekafusp alfa (onfekafusp alfa)

Snippet

Status: Application withdrawn. Therapeutic area: Melanoma. MAH: Philogen S.p.A.